Tirapazamine (Synonyms: 替拉扎明; SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone)

目錄號: HY-13767 純度: 99.73%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Tirapazamine (SR259075) 是一種抗癌劑，對實體瘤中的缺氧細胞具有選擇性細胞毒性，從而誘導(dǎo) DNA 中的單鏈和雙鏈斷裂，堿基損傷和細胞死亡。Tirapazamine (SR259075) 是一種抗癌和生物還原劑。Tirapazamine (SR259075) 能增強電離輻射對缺氧細胞的細胞毒性作用。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Tirapazamine Chemical Structure

CAS No. : 27314-97-2

1. 客戶無需承擔相應(yīng)的運輸費用。

2. 同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
10 mM * 1 mL in DMSO	￥726	In-stock
50 mg	￥660	In-stock
100 mg	￥1116	In-stock
200 mg	￥1860	In-stock
500 mg		詢價
1 g		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻

•J Nanobiotechnology. 2024 Jun 21;22(1):358. [Abstract]
•Biomaterials. 2022 Sep 27;290:121821. [Abstract]
•J Control Release. 2022 Sep 22;351:151-163. [Abstract]
•Acta Biomater. 2023 Apr 21;S1742-7061(23)00220-9. [Abstract]
•Front Bioeng Biotechnol. 2022 Feb 21;10:796820. [Abstract]
•J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
•Anal Biochem. 2021 Sep 12;114329. [Abstract]
•Nanotechnology. 2021 Jul 29. [Abstract]
•Biomater Adv. 2024 Jul 19:163:213962. [Abstract]
•Research Square Preprint. 2021 Aug.

Tirapazamine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

生物活性
純度 & 產(chǎn)品資料
參考文獻

生物活性

Tirapazamine (SR259075) is an anticancer agent that shows selective cytotoxicity for hypoxic cells in solid tumors, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death. Tirapazamine is an anticancer and bioreductive agent.Tirapazamine (SR259075) can enhance the cytotoxic effects of ionizing radiation in hypoxic cells^[1]^[2].

細胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 50 μM Compound: TPZ	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	1.93 μM Compound: TPZ	Cytotoxicity against human A549 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human A549 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
A549	GI₅₀	6.8 μM Compound: Tirapazamine	Cytotoxicity against human A549 cells incubated for 4 hrs in anoxic condition followed by oxic exposure for 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells incubated for 4 hrs in anoxic condition followed by oxic exposure for 48 hrs by sulforhodamine B assay	[PMID: 32196334]
A549	IC₅₀	6.9 μM Compound: TPZ	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	GI₅₀	63 μM Compound: Tirapazamine	Cytotoxicity against human A549 cells incubated for 52 hrs in oxic condition by sulforhodamine B assay Cytotoxicity against human A549 cells incubated for 52 hrs in oxic condition by sulforhodamine B assay	[PMID: 32196334]
A549	IC₅₀	7.43 μM Compound: TPZ	Cytotoxicity against human A549 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human A549 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
COLO 205	IC₅₀	47.7 μM Compound: Tirapazamine	Cytotoxicity against human COLO205 cells measured after 48 hrs under hypoxic condition by CCK8 assay Cytotoxicity against human COLO205 cells measured after 48 hrs under hypoxic condition by CCK8 assay	[PMID: 27140429]
H9c2	EC₅₀	> 100 μM Compound: 10; TPZ	Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
HCT-116	IC₅₀	11.9 μM Compound: Tirapazamine	Cytotoxicity against human HCT116 cells measured after 48 hrs under hypoxic condition by CCK8 assay Cytotoxicity against human HCT116 cells measured after 48 hrs under hypoxic condition by CCK8 assay	[PMID: 27140429]
HCT-116	IC₅₀	72.7 μM Compound: Tirapazamine	Cytotoxicity against human HCT116 cells measured after 18 hrs under hypoxic condition by CCK8 assay Cytotoxicity against human HCT116 cells measured after 18 hrs under hypoxic condition by CCK8 assay	[PMID: 27140429]
HepG2	IC₅₀	19.1 μM Compound: TPZ	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 16777409]
HepG2	IC₅₀	56.6 μg/mL Compound: TPZ	Growth inhibition of human HepG2 cells after 48 hrs by SRB assay Growth inhibition of human HepG2 cells after 48 hrs by SRB assay	[PMID: 20236735]
HL-60	IC₅₀	16.1 μM Compound: TPZ	Cytotoxicity against human HL60 cells in normoxia after 48 hrs Cytotoxicity against human HL60 cells in normoxia after 48 hrs	[PMID: 16777409]
HL-60	IC₅₀	2.31 μM Compound: TPZ	Ratio of cytotoxicity against human HL60 cells in normoxia to hypoxia after 48 hrs Ratio of cytotoxicity against human HL60 cells in normoxia to hypoxia after 48 hrs	[PMID: 16777409]
HL-60	IC₅₀	7 μM Compound: TPZ	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 16777409]
HL-60	IC₅₀	7 μM Compound: TPZ	Cytotoxicity against human HL60 cells in hypoxia after 48 hrs Cytotoxicity against human HL60 cells in hypoxia after 48 hrs	[PMID: 16777409]
HT-29	IC₅₀	> 50 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	> 50 μM Compound: TPZ	Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay	[PMID: 25462282]
HT-29	IC₅₀	387 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under normoxia condition by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under normoxia condition by SRB assay	[PMID: 28851503]
HT-29	IC₅₀	5.1 μM Compound: 1, TPZ	Cytotoxicity against human HT29 cells under hypoxic conditions after 4 hrs Cytotoxicity against human HT29 cells under hypoxic conditions after 4 hrs	[PMID: 18001018]
HT-29	IC₅₀	5.1 μM Compound: 1, TPZ	Cytotoxicity against human HT-29 cells after 4 hrs under strict hypoxic condition Cytotoxicity against human HT-29 cells after 4 hrs under strict hypoxic condition	[PMID: 18847185]
HT-29	IC₅₀	6.2 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under hypoxia condition by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under hypoxia condition by SRB assay	[PMID: 28851503]
HT-29	IC₅₀	9.45 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	9.45 μM Compound: TPZ	Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay	[PMID: 25462282]
K562	IC₅₀	1.81 μM Compound: TPZ	Cytotoxicity against human K562 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human K562 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
K562	IC₅₀	19.41 μM Compound: TPZ	Cytotoxicity against human K562 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human K562 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
K562	IC₅₀	5.2 μM Compound: TPZ	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 16777409]
KB	IC₅₀	18.71 μM Compound: TPZ	Cytotoxicity against human KB cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human KB cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
KB	IC₅₀	6.29 μM Compound: TPZ	Cytotoxicity against human KB cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human KB cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
MDA-MB-468	IC₅₀	1.304 μM Compound: Tirapazamine	Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
MDA-MB-468	IC₅₀	105.2 μM Compound: Tirapazamine	Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
MDCK	IC₅₀	< 50 μM Compound: Tirapazamine	Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	> 300 μM Compound: Tirapazamine	Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	> 300 μM Compound: Tirapazamine	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	95 μM Compound: Tirapazamine	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay	[PMID: 27823879]
MOLM-13	EC₅₀	22 μM Compound: 10; TPZ	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
MOLM-13	EC₅₀	22 μM Compound: 4; TPZ	Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis	[PMID: 28284865]
MOLM-13	EC₅₀	95 μM Compound: 10; TPZ	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
MOLM-13	EC₅₀	95 μM Compound: 4; TPZ	Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis	[PMID: 28284865]
MOLT-4	IC₅₀	15.8 μM Compound: TPZ	Cytotoxicity against human Molt4 cells in normoxia after 48 hrs Cytotoxicity against human Molt4 cells in normoxia after 48 hrs	[PMID: 16777409]
MOLT-4	IC₅₀	3.43 μM Compound: TPZ	Ratio of cytotoxicity against human Molt4 cells in normoxia to hypoxia after 48 hrs Ratio of cytotoxicity against human Molt4 cells in normoxia to hypoxia after 48 hrs	[PMID: 16777409]
MOLT-4	IC₅₀	4.6 μM Compound: TPZ	Cytotoxicity against human Molt4 cells after 48 hrs by MTT assay Cytotoxicity against human Molt4 cells after 48 hrs by MTT assay	[PMID: 16777409]
MOLT-4	IC₅₀	4.6 μM Compound: TPZ	Cytotoxicity against human Molt4 cells in hypoxia after 48 hrs Cytotoxicity against human Molt4 cells in hypoxia after 48 hrs	[PMID: 16777409]
NCI-H460	IC₅₀	> 100 μM Compound: tirapazamine	Cytotoxicity against human H460 cells under normoxic condition after 2 hrs by Alamar blue staining assay Cytotoxicity against human H460 cells under normoxic condition after 2 hrs by Alamar blue staining assay	[PMID: 18257544]
NCI-H460	IC₅₀	11 μM Compound: tirapazamine	Cytotoxicity against human H460 cells under hypoxic condition after 2 hrs by Alamar blue staining assay Cytotoxicity against human H460 cells under hypoxic condition after 2 hrs by Alamar blue staining assay	[PMID: 18257544]
NRK	EC₅₀	> 100 μM Compound: 10; TPZ	Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
NRK	EC₅₀	35 μM Compound: 10; TPZ	Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
PC-3	IC₅₀	1.17 μM Compound: TPZ	Cytotoxicity against human PC3 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human PC3 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
PC-3	IC₅₀	20.97 μM Compound: TPZ	Cytotoxicity against human PC3 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human PC3 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
PC-3	IC₅₀	22.3 μM Compound: TPZ	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 16777409]
SiHa	IC₅₀	2.5 μM Compound: 1, TPZ	Cytotoxicity against human SiHa cells under hypoxic conditions after 4 hrs Cytotoxicity against human SiHa cells under hypoxic conditions after 4 hrs	[PMID: 18001018]
SiHa	IC₅₀	2.5 μM Compound: 1, TPZ	Cytotoxicity against human SiHa cells after 4 hrs under strict hypoxic condition Cytotoxicity against human SiHa cells after 4 hrs under strict hypoxic condition	[PMID: 18847185]
SMMC-7721	IC₅₀	32.79 μM Compound: TPZ	Cytotoxicity against human SMMC7721 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human SMMC7721 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
SMMC-7721	IC₅₀	4.75 μM Compound: TPZ	Cytotoxicity against human SMMC7721 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human SMMC7721 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
SW-620	IC₅₀	1.2 μM Compound: Tirapazamine	Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
SW-620	IC₅₀	91.03 μM Compound: Tirapazamine	Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
U-251	IC₅₀	71.2 μg/mL Compound: TPZ	Growth inhibition of human U251 cells after 48 hrs by SRB assay Growth inhibition of human U251 cells after 48 hrs by SRB assay	[PMID: 20236735]
Vero	CC₅₀	8 μg/mL Compound: TPZ	Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay	[PMID: 22691154]

體外研究
(In Vitro)

Tirapazamine (SR259075) is the optimal drug for combination therapy using Pba^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	SCC7 cells
Concentration:	1mg
Incubation Time:	24 h
Result:	Showed synergism with Pba at ED50, ED90 and ED95.

體內(nèi)研究
(In Vivo)

Tirapazamine (SR259075) (1mg; intravenously injected; twice at a 24-h interval) shows a synergetic effect to kill tumor cells because TPZ was activated under the hypoxic conditions that originated from the PDT with Pba and laser irradiation^[1].
.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C3H/HeN mice^[1].
Dosage:	1mg
Administration:	Tirapazamine (1mg; intravenously injected; twice at a 24-h interval)
Result:	Suppressed the tumors of mice by using laser irradiation.

Clinical Trial

分子量

178.15

Formula

C₇H₆N₄O₂

CAS 號

27314-97-2

性狀

固體

顏色

Orange to red

中文名稱

替拉扎明

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性數(shù)據(jù)

細胞實驗：

DMSO 中的溶解度 : 62.5 mg/mL (350.83 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	5.6132 mL	28.0662 mL	56.1325 mL
5 mM	1.1226 mL	5.6132 mL	11.2265 mL
10 mM	0.5613 mL	2.8066 mL	5.6132 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據(jù)您的實驗動物和給藥方式選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: 2.5 mg/mL (14.03 mM); 懸濁液; 超聲助溶

此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。
方案二

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (11.68 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案三

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (11.68 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： 50% PEG300 50% Saline
Solubility: 10 mg/mL (56.13 mM); 懸濁液; 超聲助溶

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.73%

選擇批次：

Data Sheet (631 KB) SDS (393 KB)

COA (266 KB) LCMS (111 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻

[1]. Cai TY, et al. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Mol Cancer Ther. 2014 Mar;13(3):630-42. [Content Brief]

[2]. Sliwinska J, et al. Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca2? balance protein levels. Oxid Med Cell Longev. 2012;2012:890826. [Content Brief]

[3]. Lee, Donghyun, et al. Optimized Combination of Photodynamic Therapy and Chemotherapy Using Gelatin Nanoparticles Containing Tirapazamine and Pheophorbide a. ACS applied materials & interfaces vol. 13,9 (2021): 10812-10821. [Content Brief]

[4]. Romero, José, et al. Electronic structure and reactivity of tirapazamine as a radiosensitizer. Journal of molecular modeling vol. 27,6 177. 22 May. 2021. [Content Brief]

Tirapazamine 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.6132 mL	28.0662 mL	56.1325 mL	140.3312 mL
	5 mM	1.1226 mL	5.6132 mL	11.2265 mL	28.0662 mL
	10 mM	0.5613 mL	2.8066 mL	5.6132 mL	14.0331 mL
	15 mM	0.3742 mL	1.8711 mL	3.7422 mL	9.3554 mL
	20 mM	0.2807 mL	1.4033 mL	2.8066 mL	7.0166 mL
	25 mM	0.2245 mL	1.1226 mL	2.2453 mL	5.6132 mL
	30 mM	0.1871 mL	0.9355 mL	1.8711 mL	4.6777 mL
	40 mM	0.1403 mL	0.7017 mL	1.4033 mL	3.5083 mL
	50 mM	0.1123 mL	0.5613 mL	1.1226 mL	2.8066 mL
	60 mM	0.0936 mL	0.4678 mL	0.9355 mL	2.3389 mL
	80 mM	0.0702 mL	0.3508 mL	0.7017 mL	1.7541 mL
	100 mM	0.0561 mL	0.2807 mL	0.5613 mL	1.4033 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報使用等其他用途提供服務(wù)。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tirapazamine (Synonyms: 替拉扎明; SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone)

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻

Tirapazamine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

摩爾計算器

稀釋計算器

Tirapazamine 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tirapazamine (Synonyms: 替拉扎明; SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone)

Customer Review

Tirapazamine 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻

Tirapazamine 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點產(chǎn)品:

•同靶點蛋白產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻

Tirapazamine 相關(guān)抗體:

摩爾計算器

稀釋計算器

Tirapazamine 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z